Johnson & Johnson said Wednesday that it is significantly scaling its regional footprint with a $1 billion+ investment in a next-generation cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania.
While the new plant is located across the Delaware River in Montgomery County, the strategic move is being driven from J&J’s global headquarters in New Brunswick. The project is a central pillar of the company’s massive $55 billion U.S. investment plan through 2029, aimed at reshoring the production of advanced medicines.
The Lower Gwynedd facility will focus on “multimodal” cell therapy—a cutting-edge field where a patient’s own cells are reprogrammed to fight cancer, as well as immune and neurological diseases.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy,” Joaquin Duato, chairman and CEO said.
By the numbers, the project is a major win for the regional economy:
-
4,000+ Construction Jobs: Stimulating the local building trades during site development.
-
500+ Biomanufacturing Roles: High-paying, technical positions for the regional STEM workforce.
-
$10 Billion Impact: Strengthening J&J’s existing annual economic contribution to the state.
The move further solidifies the Philadelphia-to-New-Jersey corridor as the nation’s premier life sciences hub. J&J already maintains ten facilities in Pennsylvania totaling over 2 million square feet, but the New Brunswick-based leadership sees this latest expansion as critical for meeting U.S. patient demand without relying on fragile international supply chains.
Pennsylvania Gov. Josh Shapiro praised the move, noting that Pennsylvania is “competing and winning” in the biotech space by cutting red tape and following a strategic economic development plan.
The investment also aligns with broader national trends. In early 2026, J&J was among several pharmaceutical giants to strike deals with the federal government to stabilize drug pricing and domestic production. This $1 billion facility serves as a tangible commitment to manufacturing “the vast majority” of its advanced medicines within U.S. borders.
For New Jersey residents and the thousands of J&J employees in the Garden State, the expansion represents the continued growth of a local company that has evolved into a global “innovation powerhouse” while keeping its roots—and its decision-making—firmly in New Brunswick.
